Rocket Pharmaceuticals Inc (NAS:RCKT)

$ 22.23 0.3 (1.37%) Market Cap: 2.02 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 4.56 GF Score: 39/100

Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Rocket Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Rocket Pharmaceuticals Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript
Apr 25, 2023
Rocket Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Krystal Biotech Inc, Affyimmune Therapeutics Inc, Rocket Pharmaceuticals Inc and Iovance Biotherapeutics Inc at Endpoints Webinar on Moving CGTx Clinical Development- Panel Transcript
Mar 02, 2023
Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Rocket Pharmaceuticals Inc Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 Transcript
Sep 30, 2022
Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript
Sep 20, 2022
Rocket Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Rocket Pharmaceuticals Inc, Decibel Therapeutics Inc and Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference- Panel Transcript
Sep 07, 2022
Rocket Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript
May 24, 2022
Rocket Pharmaceuticals Inc at Needham Healthcare Conference Transcript
Apr 11, 2022
Rocket Pharmaceuticals Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Apr 01, 2022
Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Rocket Pharmaceuticals Inc to Host In-Person Investor and Analyst Event Transcript
Dec 14, 2021
Rocket Pharmaceuticals Inc Danon Update Call Transcript
Nov 15, 2021
Q2 2021 Rocket Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2021

$33.63 (-3.20%)

Earnings
Rocket Pharmaceuticals Inc to Discuss Danon Program Call Transcript
May 10, 2021
Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Rocket Pharmaceuticals, Inc. - Special Call Transcript
Dec 08, 2020
Rocket Pharmaceuticals, Inc. - Special Call Transcript
Dec 07, 2020
Rocket Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Rocket Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2020
Rocket Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Rocket Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Rocket Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 10, 2020
Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 14, 2020
Rocket Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Rocket Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019

Rocket Pharmaceuticals, Inc. - Special Call Transcript

Dec 08, 2020 / 09:15PM GMT

Release Date Price: $32.03 (-3.73%)

Transcript

Operator

Welcome to the Phase I data for RP-A501 gene therapy for Danon Disease conference call. My name is Adrian, and I'll be your operator for today's call. (Operator Instructions)

I'll now turn the call over to Claudine Prowse, Senior Vice President of Strategy and Corporate Development. You may begin.

Claudine Prowse

Rocket Pharmaceuticals, Inc. - Senior VP of Strategy and Head of IR & Corporate Development

Thank you so much. Good evening, everyone, and thanks for joining us as we provide, for the first time, clinical results from our Phase I trial from our gene therapy program for Danon Disease. This is Claudine Prowse. I'm Senior Vice President of Strategy and Corporate Development at Rocket. And I'm joined by several members of the Rocket leadership team today, including CEO and President, Dr. Gaurav Shah; Kinnari Patel, our Chief Operating Officer; Dr. Jonathan Schwartz, our Chief Medical Officer; Dr. Jose Trevejo, Senior Vice President and Global Program Head of our AAV Program; and Dr. Brian Beard, Associate Vice President of CMC.

We

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.